breast-cancer

Multiple versions of a single RNA molecule control cancer cell division and p53 signaling in distinct ways

Long non-coding RNAs (lncRNAs) don't encode proteins but profoundly shape gene regulation, and many are highly expressed in aggressive cancers. MANCR is one such lncRNA, highly active in triple-negative breast cancer (TNBC) where it promotes genomic instability. But MANCR isn't a single molecule — it comes in at least seven isoforms, and this study asked whether those isoforms are functionally interchangeable.

Integrating computational analysis with experiments, the researchers found that specific MANCR isoforms selectively regulate different aspects of cancer cell biology: some target epigenomic control (chromatin modification), while others interfere with p53-dependent DNA damage response pathways. This isoform-specific activity is tumor-type dependent.

The findings matter for therapeutic targeting: blocking all MANCR indiscriminately may produce different effects than targeting specific isoforms, and isoform selectivity could be a vulnerability worth exploiting.

Key Findings

MANCR has at least seven isoforms with distinct, selective functional roles
Different isoforms mediate epigenomic control versus p53 pathway interference
MANCR isoform expression patterns are tumor-type specific
Isoform-specific activity was validated computationally and experimentally in TNBC
Selective targeting of MANCR isoforms may be preferable to pan-MANCR inhibition

Implications

This work refines the therapeutic targeting strategy for MANCR in TNBC and potentially other cancers. It also contributes to the broader understanding that lncRNA isoforms are not redundant — individual splice variants can have distinct regulatory activities. Isoform-selective antisense oligonucleotides or other RNA-targeting modalities could exploit these differences.

Caveats

Preprint — not peer reviewed. Based on abstract only. Largely mechanistic, early-stage research. In vivo validation not described in abstract. Therapeutic translation of lncRNA targeting remains technically challenging.

Source: bioRxiv — 2026-04-08

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.